Stay updated with breaking news from Erik Kopp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company plans to initiate trial following recent meeting with FDA No FDA-approved therapies for acute treatment of AAD are currently available NEW HAVEN, Conn., April 10, 2024 -- BioXcel...
NEW HAVEN, Conn., Feb. 13, 2024 -- BioXcel Therapeutics, Inc. , a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and...
Standardizes and improves product reimbursement process New HCPCS Level II code J1105 to be effective January 1, 2024 NEW HAVEN, Conn., Oct. 30, 2023 -- BioXcel Therapeutics, Inc. , a...
Meetings scheduled with FDA in October and November for TRANQUILITY and SERENITY III programs Company strengthens IGALMI™ market exclusivity through receipt of two Notices of Allowance ...
BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal - read this article along with other careers information, tips and advice on BioSpace